Search Results for "eric"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for eric. Results 71 to 80 of 317 total matches.
Zingo for Local Analgesia in Children
The Medical Letter on Drugs and Therapeutics • Aug 25, 2008 (Issue 1293)
: Susan Morey, Pharm.D.
CONTRIBUTING EDITOR: Eric J. Epstein, M.D. Albert Einstein College of
Medicine ...
The FDA has approved the marketing of a new device for delivering lidocaine to the skin of children undergoing a venipuncture or intravenous (IV) line placement. Zingo (Anesiva) is a powder intradermal injection system.
In Brief: Melamine
The Medical Letter on Drugs and Therapeutics • Oct 20, 2008 (Issue 1297)
K. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D. Albert ...
Melamine present in infant formula and other milk products has been associated with widespread illness and some deaths among infants in China. It was also identified in pet food sold in North America after a large number of pets became ill and some died. In both the infants and the pets, renal injury appeared to be the cause.1Melamine (C3H6N6) is a heterocyclic compound, two-thirds nitrogen by weight, that is slightly soluble in water. When combined with formaldehyde, it forms melamine resin, which has a wide variety of industrial applications including the manufacturing of kitchenware,...
In Brief: New Propellants for Albuterol Metered-Dose Inhalers
The Medical Letter on Drugs and Therapeutics • Nov 03, 2008 (Issue 1298)
Eric J. Epstein, M.D. Albert Einstein College of Medicine
CONTRIBUTING EDITOR, DRUG INTERACTIONS ...
Inhaled drugs for asthma are available in the US mainly in pressurized metered-dose inhalers (MDIs), which require a propellant, and dry powder inhalers, which do not. The chlorofluorocarbon (CFC) propellants in MDIs are being replaced by hydrofluoroalkane (HFA) propellants for environmental reasons: CFCs contribute to the depletion of the ozone layer. December 31, 2008 will be the last day that albuterol MDIs using CFC propellants can be sold in the US. The FDA is expected to announce a termination date for other CFC-containing products in the near future.Three HFA albuterol inhalers and one...
In Brief: Fluoroquinolones and Tendon Injuries
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008 (Issue 1300)
Eric J. Epstein, M.D. Albert Einstein College of Medicine
ADVISORY BOARD:
Jules Hirsch, M.D ...
The FDA has added a boxed warning to fluoroquinolone package inserts about tendon injuries that may occur as a result of their use. Tendinitis or tendon rupture may occur rarely with systemic use of any fluoroquinolone, either while the drug is being taken or for up to several months afterwards.Fluoroquinolone-related tendon injury is rare; estimates for its incidence in the general population range from 0.14% to 0.4%. The risk is higher for patients >60 years old and for those taking corticosteroids. For patients with organ transplants, the incidence may be as high as 15%.1 A case-control...
In Brief: Different Diets
The Medical Letter on Drugs and Therapeutics • Mar 23, 2009 (Issue 1308)
and Surgeons
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D ...
A recent article in the New England Journal of Medicine confirms something that others, including The Medical Letter (Treat Guidel Med Lett 2008; 6:23), have been saying for years: no particular combination of protein, carbohydrate and fat in the diet offers any advantage in losing weight. This randomized 2-year trial followed 800 overweight and obese subjects on low fat/average protein, low fat/high protein, high fat/average protein, and high fat/high protein diets. Carbohydrate intake varied from 35% (in the high fat/high protein diet) to 65% (in the low fat/average protein diet). All...
In Brief: Plan B for 17-Year Olds
The Medical Letter on Drugs and Therapeutics • May 18, 2009 (Issue 1312)
. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D. Albert Einstein ...
The FDA has announced that it will lower the age for over-the-counter access to the emergency contraceptive Plan B1 from 18 to 17 years old. In a randomized, controlled trial, the two 0.75-mg levonorgestrel tablets in Plan B, taken 12 hours apart beginning within 72 hours after unprotected intercourse, decreased the overall pregnancy rate to 1.1% (11/976) of women who requested emergency contraception.2 The sooner the drug is taken after coitus, the more effective it is. Nausea and vomiting can occur with Plan B. Fetal malformations have not been associated with pregnancies that occurred...
In Brief: Injectable Paliperidone Palmitate for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009 (Issue 1324)
. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D. Albert Einstein ...
Paliperidone palmitate (Invega Sustenna – Ortho-McNeil Janssen) has been approved by the FDA as a once-monthly injection for acute and maintenance treatment of schizophrenia in adults. An extended-release oral formulation (Invega) has been available since 2006.1 Long-acting injections of antipsychotic drugs typically are used to treat patients who cannot adhere to an oral regimen.2,3 Paliperidone is the primary active metabolite of risperidone (Risperdal), which is also available as a long-acting (every 2 weeks) injection. It is unclear whether either risperidone or paliperidone is a better...
Arformoterol (Brovana) for COPD
The Medical Letter on Drugs and Therapeutics • Jul 02, 2007 (Issue 1264)
., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein College of Medicine
SENIOR ...
Arformoterol tartrate (Brovana - Sepracor), a singleisomer, long-acting beta2-agonist, has been approved by the FDA as an inhalation solution for nebulization for treatment of bronchoconstriction pulmonary disease (COPD). Arformoterol is the (R,R)-enantiomer of formoterol (Foradil), which is available as a powder for inhalation and was recently also approved as a solution for nebulization (Perforomist - Dey; available fall 2007)
Low-Dose Transdermal Estrogens
The Medical Letter on Drugs and Therapeutics • Aug 27, 2007 (Issue 1268)
., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein College of Medicine
SENIOR ...
Three low-dose transdermal estrogens were recently approved by the FDA for treatment of menopausal vasomotor symptoms. Elestrin and Divigel are transdermal estradiol gels and Evamist is an estradiol spray. Elestrin has been marketed in Europe since 1976.
Aspirin for Primary Prevention of Cardiovascular Disease (Revisited)
The Medical Letter on Drugs and Therapeutics • Jul 03, 2006 (Issue 1238)
of Medicine
EDITORIAL FELLOWS:
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric ...
When the use of aspirin for primary prevention of cardiovascular diseases was last reviewed in The Medical Letter, only one placebo-controlled prospective trial was available: the (male) Physicians' Health Study. Last year, a second large, randomized, placebo-controlled study was reported as part of the Women's Health Study. Recently a sex-specific meta-analysis of 6 trials, including these two, was published.